Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAEL-101 plus plasma cell dyscrasia treatment versus placebo plus plasma cell dyscrasia treatment in treatment-naive Mayo stage IIIa AL amyloidosis
NL-OMON51374Phase 3Withdrawn
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in light-chain amyloidosis comparing CAEL-101 plus standard plasma cell dyscrasia treatment with Placebo plus standard plasma cell dyscrasia treatment (2 arms). Primary endpoints: Primary efficacy endpoint and Primary safety endpoint. Planned start Mar 2022; status: withdrawn.
02
Drugs
anselamimab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NL-OMON51374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51374.